发布时间：2025-09-04 10:26



BAAR, Switzerland--(BUSINESS WIRE)--Stallergenes Greer, a global leader in allergy therapeutics, and Nuance Pharma, an innovation-focused biopharmaceutical company based in China, today announced they have entered into an exclusive long-term partnership agreement regarding the development and commercialisation of Actair®, Stallergenes Greer’s sublingual allergen immunotherapy (SLIT) tablet for the treatment of house dust mite (HDM) induced allergic rhinitis.

Under the terms of the partnership agreement, Stallergenes Greer and Nuance Pharma will work together on the development and registration of Actair®in China. Nuance Pharma would be responsible for the subsequent commercialisation of Actair® on the Chinese market.

“We are excited by the prospects of this strategic partnership for Actair®in China. By leveraging Stallergenes Greer’s strong heritage in respiratory allergen immunothera
=*=*=*=*=*=
当前为第1/6页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页